Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Cutaneous Melanoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
8 drugs · 42 active trials
0 drugs · 0 active trials
no drug at this stage
1 drug · 11 active trials
Data updated 6 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Lifileucel | Phase 1 | Phase 1 | 2 | 0 | 0 | 3 | 0 | — | — | Feb 6, 2023 |
| Melphalan | Phase 1 | Phase 1 | 2 | 0 | 0 | 3 | 0 | — | — | Feb 6, 2023 |
| Akt Inhibitor MK2206 | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 23, 2011 |
| Hydroxychloroquine | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 23, 2011 |
| Ruxolitinib | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 9, 2022 |
| Abemaciclib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 29, 2016 |
| Abexinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 20, 2018 |
| Brentuximab Vedotin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 29, 2020 |
| Etoposide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 31, 2018 |
| FACT Complex-targeting Curaxin CBL0137 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 1, 2019 |
| Imiquimod | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 20, 2017 |
| Obinutuzumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 28, 2020 |
| Onalespib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 29, 2014 |
| Pegargiminase | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-09 |
| Pegfilgrastim | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 5, 2016 |
| Ramucirumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 29, 2016 |
| Romidepsin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 3, 2012 |
| Sirolimus | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-03 |
| Tremelimumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 10, 2012 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.